View Clinical Trial (Medical Research Study)

A Study to Describe the Pharmacokinetics of Acyclovir in Infants - NCT00942084-27713(Clinical Trial 302693)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Durham
State:  
NC
Zip Code: 27713
Conditions: Herpes Simplex Virus - Neonatal Sepsis
Purpose: Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies. Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been adequately studied in full-term or premature neonates. HSV is a very serious infection in babies <6 months of age and often results in death or profound mental retardation. HSV leads to profound mental retardation in young infants because the virus attacks the central nervous system. The investigators hypothesize that the currently recommended dose of acyclovir is inadequate to produce adequate blood levels to combat herpes simplex infection. The investigators propose to study acyclovir levels in the blood of babies who are placed on acyclovir to treat a suspected HSV infection. This will allow them to determine the appropriate dose in premature infants. This is an unmet public health need because it is likely that the drug behaves differently in premature infants than it does in term infants and older children. Premature babies have more body water and less body tissue. Their kidneys are more immature and do not function as well as full term infants. Premature neonates are also at the greatest risk from herpes infection because they have poorly functioning immature immune systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in term infants.
Study summary: Neonatal HSV carries a major risk of death if untreated. Although acyclovir has reduced mortality dramatically, morbidity remains high. The pharmacokinetics of acyclovir have not been adequately studied in neonates less than 48 hours old. The primary objective is to assess the pharmacokinetics of intravenously administered acyclovir at a single institution in infants younger than 120 days of age with suspected Herpes Simplex Virus (HSV) infection. We plan to enroll 32 infants within the first 2 months of life. We will administer acyclovir every 8 hours for 5-10 days. We will draw levels at 1, 2-4, and 6-8 hours after the initial dose in order to determine first-dose kinetics. In order to determine steady state kinetics, we will also draw levels at immediately prior to, and at 1, 2-4, and 6-8 hours after a steady state dose (Dose 5-15).
Criteria: The investigator or other study site personnel must document in the source documents (e.g., the hospital chart) that the informed consent was obtained. Laboratory tests or non-pharmacologic treatment procedures that were performed and considered "standard of care" within 72 hours may be used for screening procedures required by the protocol and recorded in the CRF. The presence of inclusion criteria and the absence of exclusion criteria will be verified on the CRF. Inclusion Criteria: 1. Infant < 60 days old at the time of initial study drug administration. 2. Patient must have sufficient venous access to permit administration of study medication. 3. Infant suspected to have systemic infection and appropriate cultures (blood +/- urine/CSF) are obtained within 48 hours of study entry. Urine and CSF cultures will be obtained based on clinical index of suspicion, but are not required for enrollment. 4. Availability and willingness of the parent/legally authorized representative to provide written informed consent. Exclusion Criteria: 1. Patients with a history of anaphylaxis attributed to acyclovir. 2. Renal dysfunction indicated by serum creatinine >1.7 mg/dL 3. Previous participation in the study. 4. Any other concomitant condition, which in the opinion of the investigator would preclude a patient's participation in the study.
Study is available at: Duke University
Durham, NC 27713
United States

Primary Contact:
Robert W Lenfestey, M.D.
Email: lenfe001@mc.duke.edu
Phone: 919-684-9298

Secondary Contact:
Robert W Lenfestey, M.D.
Email: lenfe001@mc.duke.edu
Phone: 919-684-9298
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.